Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults

Next Previous
Search
Trial Profile

A Randomized, Double-blind Study of the Safety and Efficacy of GSK1349572 50 mg Once Daily Versus Raltegravir 400 mg Twice Daily, Both Administered With an Investigator-selected Background Regimen Over 48 Weeks in HIV-1 Infected, Integrase Inhibitor-Naïve, Antiretroviral-Experienced Adults

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 07 Sep 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dolutegravir (Primary) ; Antiretrovirals; Raltegravir
  • Indications HIV-1 infections
  • Focus Pharmacogenomic; Registrational; Therapeutic Use
  • Acronyms SAILING
  • Sponsors ViiV Healthcare

    • Most Recent Events

    • 02 Aug 2022 Results (n=29) of a 10-year follow-up analysis assessing virologic outcomes and viral resistance in subpopulation receiving DTG plus dual NRTIs presented at the 24th International AIDS Conference
    • 15 Jan 2021 Status changed from active, no longer recruiting to completed.
    • 02 Mar 2020 Planned End Date changed from 29 Jun 2020 to 18 Dec 2020.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top